Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (1,463 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-02-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: smallmutationcell lungwith chronicegfr
  Phrases that lowered it: diseasesdisorderaccordingseverelaboratory
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 30.7% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 6 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 95.1% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Phase: 3 (raises risk) · Design
• Drug's FAERS reports before start: 5983 (raises risk) · Drug's FDA history
• Keywords listed: 0 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients NCT01040780 · started 2009 · scored riskier than 70% of active trials completed
• Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation NCT01996098 · started 2014 · scored riskier than 46% of active trials terminated
• Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy NCT02486354 · started 2010 · scored riskier than 20% of active trials completed
• Icotinib for Completed Resected IB NSCLC With EGFR Mutation NCT02264210 · started 2015 · scored riskier than 70% of active trials completed
• EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression NCT03544814 · started 2015 · scored riskier than 50% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.